What is Countable Labs?
Countable Labs operates at the intersection of biotechnology and molecular diagnostics, specializing in the development of high-sensitivity DNA quantification tools. By reimagining traditional PCR-based methodologies, the company provides innovative solutions that simplify complex workflows in genomic analysis. Their technology is designed to enhance the accuracy and accessibility of biological insights, serving a diverse range of applications including biomarker research, gene therapy development, and clinical diagnostics. Through its commitment to technical excellence, Countable Labs is establishing itself as a foundational player in the life sciences sector, enabling the next generation of precision medicine.
How much funding has Countable Labs raised?
Countable Labs has raised a total of $26M across 1 funding round:
Unspecified
$26M
Unspecified (2026): $26M with participation from F-Prime Capital Partners, Primer Ventures, and ARCH Venture Partners
Key Investors in Countable Labs
F-Prime Capital Partners
A global venture capital firm with a deep focus on healthcare and technology, leveraging a team of scientists and clinicians to support transformative life science ventures.
Primer Ventures
An investment firm dedicated to early-stage life science tools and therapeutics, with a specific emphasis on genomics, synthetic biology, and molecular diagnostics.
ARCH Venture Partners
A premier venture capital firm specializing in the commercialization of breakthrough innovations in life sciences and advanced technologies, often co-founding companies with leading researchers.
What's next for Countable Labs?
With the recent infusion of capital, Countable Labs is poised to scale its operational capacity and broaden its market reach. The company intends to leverage these funds to optimize its molecular measurement solutions, focusing on the commercialization of its core technologies for broader clinical adoption. Strategic priorities include the enhancement of diagnostic workflows and the integration of their platforms into existing gene therapy research pipelines. As the firm continues to refine its genomic analysis capabilities, it remains focused on driving long-term value for stakeholders while maintaining its commitment to scientific rigor and innovation in the biotechnology space.
See full Countable Labs company page
